Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.
We currently have 32 topical Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $2.0 billion (IMS, July 2017).
We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.
As we grow, we will keep our focus on execution, ownership and delivering on what we promise.
Jenniffer Collins
CFO
Recent News
Teligent, Inc. Announces FDA Approval of Partnered ANDA for Desonide Lotion, 0.05%
BUENA, N.J. , Oct. 02, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic phar...
( FY 2017 )
